<DOC>
	<DOC>NCT01247766</DOC>
	<brief_summary>The purpose of this study is to compare the incidence rates of infection, malignancy and death among patients with rheumatoid arthritis who are treated with abatacept and those who are treated with other anti-rheumatic medications for rheumatoid arthritis.</brief_summary>
	<brief_title>Safety Study of Abatacept to Treat Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Rheumatoid arthritis Receipt of abatacept, other biologic diseasemodifying drug, or any non biologic diseasemodifying antirheumatic drug Age 18 years or older Below 18 years of age</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>